Kelun-Biotech's Core product Trastuzumab Botidotin Approved for Marketing by NMPA for HER2-positive BC ...Middle East

CHENGDU, China, Oct. 17, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that the Company's human epidermal growth factor receptor 2 (HER2)-directed antibody-drug conjugate (ADC) trastuzumab botidotin (also known as A166) was approved for...

Hence then, the article about kelun biotech s core product trastuzumab botidotin approved for marketing by nmpa for her2 positive bc was published today ( Friday 17/10/2025 - 12:44 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Kelun-Biotech's Core product Trastuzumab Botidotin Approved for Marketing by NMPA for HER2-positive BC )

Also on site :

• Brighton student guilty of raping multiple women
• Nordstrom Rack Has a 'Gorgeous' $240 Wrap Coat on Sale for Just $100 — and It Comes in 4 Colors
• The Predator in the Church Basement